Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
Aged
Capillary Leak Syndrome
/ chemically induced
Child
Dendritic Cells
Drug Approval
Drug Evaluation, Preclinical
Drug Labeling
Hematologic Neoplasms
/ drug therapy
Humans
Interleukin-3 Receptor alpha Subunit
/ antagonists & inhibitors
Precision Medicine
Prognosis
Recombinant Fusion Proteins
/ adverse effects
Thrombocytopenia
/ chemically induced
Transaminases
/ blood
Journal
Minerva medica
ISSN: 1827-1669
Titre abrégé: Minerva Med
Pays: Italy
ID NLM: 0400732
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
22
9
2020
medline:
15
12
2020
entrez:
21
9
2020
Statut:
ppublish
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy, characterized by poor prognosis if treated with conventional therapy. Allogenic hematologic stem cell transplant can improve survival and can be curative, but it is available in a small percentage of patients given that the median age at diagnosis is 70 years. In this scenario it is assumed that only the development of precision medicine-driven therapy will change BPDCN patient prognosis. CD123 (the α-subunit of interleukin (IL)-3 receptor) is over-expressed on BPDCN cells surface and seems to be the ideal marker to develop antibody-based therapies. Tagraxofusp (Elzonris
Identifiants
pubmed: 32955827
pii: S0026-4806.20.07018-4
doi: 10.23736/S0026-4806.20.07018-4
doi:
Substances chimiques
IL3RA protein, human
0
Interleukin-3 Receptor alpha Subunit
0
Recombinant Fusion Proteins
0
tagraxofusp
8ZHS5657EH
Transaminases
EC 2.6.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM